A Deep Dive Into Aquestive Following The FDA's Approval Of Riluzole

Aquestive Therapeutics Inc (NASDAQ: AQST) made a move this week, gaining about 17% Monday after the FDA approved one of its drugs ahead of a Nov. 30 PDUFA action date. The company is expected to complete the rolling regulatory submission for another investigational drug before the end of November. Aquestive is a specialty pharma company that primarily focuses on therapies for central nervous system conditions.

from Yahoo Finance https://ift.tt/35G0ZvI